- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/24 - Antidepressants
Patent holdings for IPC class A61P 25/24
Total number of patents in this class: 4103
10-year publication summary
124
|
115
|
164
|
244
|
297
|
310
|
368
|
407
|
410
|
112
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Takeda Pharmaceutical Company Limited | 2961 |
77 |
Janssen Pharmaceutica N.V. | 3839 |
69 |
F. Hoffmann-La Roche AG | 7958 |
58 |
Antecip Bioventures II LLC | 300 |
53 |
Sage Therapeutics, Inc. | 312 |
53 |
AstraZeneca AB | 3042 |
44 |
Taisho Pharmaceutical Co., Ltd. | 844 |
43 |
H. Lundbeck A/S | 1252 |
41 |
Hoffmann-La Roche Inc. | 3060 |
36 |
Sumitomo Dainippon Pharma Co., Ltd. | 226 |
27 |
GH Research Ireland Limited | 33 |
25 |
Intra-Cellular Therapies, Inc. | 378 |
23 |
Sunshine Lake Pharma Co., Ltd. | 542 |
23 |
The Regents of the University of California | 18943 |
22 |
Boehringer Ingelheim International GmbH | 4629 |
22 |
Les Laboratoires Servier | 599 |
22 |
LTS Lohmann Therapie-Systeme AG | 691 |
22 |
Glaxo Group Limited | 4496 |
21 |
Dainippon Sumitomo Pharma Co., Ltd. | 234 |
21 |
Novartis AG | 11238 |
20 |
Other owners | 3381 |